Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Purinergic Receptors in Basal Ganglia Diseases: Shared Molecular Mechanisms between Huntington's and Parkinson's Disease

Full text
Show less -
Glaser, Talita [1] ; Andrejew, Roberta [1] ; Oliveira-Giacomelli, Agatha [1] ; Ribeiro, Deidiane Elisa [1] ; Marques, Lucas Bonfim [1] ; Ye, Qing [1, 2] ; Ren, Wen-Jing [2, 3] ; Semyanov, Alexey [4, 5] ; Illes, Peter [3, 6] ; Tang, Yong [2, 6] ; Ulrich, Henning [1]
Total Authors: 11
[1] Univ Sao Paulo, Inst Chem, Dept Biochem, Av Prof Lineu Prestes 748, BR-05508000 Sao Paulo, SP - Brazil
[2] Key Lab Sichuan Prov Acupuncture & Chronobiol, Chengdu 610075 - Peoples R China
[3] Univ Leipzig, Rudolf Boehm Inst Pharmakol & Toxikol, D-04107 Leipzig - Germany
[4] Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997 - Russia
[5] Sechenov First Moscow State Med Univ, Moscow 119992 - Russia
[6] Chengdu Univ Tradit Chinese Med, Int Collaborat Ctr Big Sci Plan Purine Signaling, Chengdu 610075 - Peoples R China
Total Affiliations: 6
Document type: Review article
Source: NEUROSCIENCE BULLETIN; v. 36, n. 11, SI, p. 1299-1314, NOV 2020.
Web of Science Citations: 3

Huntington's (HD) and Parkinson's diseases (PD) are neurodegenerative disorders caused by the death of GABAergic and dopaminergic neurons in the basal ganglia leading to hyperkinetic and hypokinetic symptoms, respectively. We review here the participation of purinergic receptors through intracellular Ca(2+)signaling in these neurodegenerative diseases. The adenosine A(2A)receptor stimulates striatopallidal GABAergic neurons, resulting in inhibitory actions on GABAergic neurons of the globus pallidus. A(2A)and dopamine D2 receptors form functional heteromeric complexes inducing allosteric inhibition, and A(2A)receptor activation results in motor inhibition. Furthermore, the A(2A)receptor physically and functionally interacts with glutamate receptors, mainly with the mGlu5 receptor subtype. This interaction facilitates glutamate release, resulting in NMDA glutamate receptor activation and an increase of Ca(2+)influx. P2X7 receptor activation also promotes glutamate release and neuronal damage. Thus, modulation of purinergic receptor activity, such as A(2A)and P2X7 receptors, and subsequent aberrant Ca(2+)signaling, might present interesting therapeutic potential for HD and PD. (AU)

FAPESP's process: 18/07366-4 - Purine and kinin receptors as targets of study and therapeutic interventions in neurological diseases
Grantee:Alexander Henning Ulrich
Support type: Research Projects - Thematic Grants
FAPESP's process: 19/24553-5 - The role of P2Y1 receptor in Parkinsons Disease
Grantee:Roberta Andrejew Caetano
Support type: Scholarships in Brazil - Doctorate
FAPESP's process: 18/17504-5 - Behavioral and molecular effects of pharmacological modulation of the P2Y2 receptors in an animal model of Alzheimer's Disease
Grantee:Deidiane Elisa Ribeiro
Support type: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 19/26852-0 - Study of purinergic receptors antagonism in the inflammatory process and microglial cells activation using in vitro and in vivo models of Parkinsons Disease
Grantee:Ágatha Oliveira Giacomelli
Support type: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 15/13345-1 - Huntington's disease: Huntingtin roles during cell fate decision
Grantee:Talita Glaser
Support type: Scholarships in Brazil - Post-Doctorate